Screening of Various Parts of Phaleria macrocarpa Plant for -Glucosidase Inhibitory Activity

Phaleria macrocarpa is an herbal plant used in Malaysia to enhance vitality. The aim of this study was to screen the -glucosidase inhibitory activity of different parts (fruit flesh, leaves and stem) of P.macrocarpa. Methanol (polar) and n-hexane (nonpolar) extracts, obtained by room temperature solvent extraction, were evaluated for in vitro -glucosidase activity inhibition. The compounds were identified by using gas chromatography-mass spectrometry (GC-MS) according to their similarity index of >70%, which might be responsible for -glucosidase inhibitory activity. The methanol extract of the fruit flesh had the highest yield (25.60.5%), whereas the n-hexane extract of the stem is more effective against -glucosidase activity (IC50 0.8 +/- 0.1g/mL). The fruit flesh (IC(50)1.3 +/- 0.2g/mL) and leaves (IC(50)1.6 +/- 0.6g/mL) had also well effectively. The identified metabolites are predominantly phenolics, carbohydrates, triterpenes and organic acids, such as D-fructose, squalene, -linolenic acid and -D-glucopyranoside. In-depth chemical profiling using GC-MS was performed for the first time for this plant to assess the likely compounds present in the extract that could be associated with anti-hyperglycemic activity. Of the three parts tested, every part indicates the potential -glucosidase inhibitory activity and hexane extract of stem showed more inhibitory activity among all extracts. Thus, P.macrocarpa can attenuate hyperglycemia by potently inhibiting carbohydrate hydrolyzing enzymes, making it a viable plant as a source of natural compounds for the management of type 2 diabetes mellitus. Practical ApplicationP.macrocarpa (Scheff.) Boerl. belongs to the Thymelaeaceae family, which is known as Mahkota Dewa is one of the well-known traditional herbs in South Asian countries. Every part of this plant has been reported to be used as a traditional medicine for diabetic treatment for many years. In the present study, the ability of this plant to inhibit carbohydrate hydrolyzing enzymes (-glucosidase) was explored. All extracts tested exhibited the content to inhibit yeast -glucosidase enzymes in vitro, and these beneficial effects appear to be due to some bioactive compounds in P.macrocarpa. Our preliminary investigation gives a principle for further animal and clinical studies of a possible use of P.macrocarpa for the management of diabetes mellitus.